A Case of Successful Treatment of Huge Pseudoaneurysm Complicated with Endovascular Intervention Using Thrombin Injection / 대한혈관외과학회지

Iatrogenic femoral pseudoaneurysm (IPA) is a troublesome complication related to the femoral arterial access site used for invasive cardiovascular procedures. Several therapeutic strategies have been developed to treat this complication. They include surgical repair, ultrasound-guided compression repair, and minimally invasive percutaneous treatments (thrombin injection, coil embolization, and insertion of covered stents). Traditionally, surgical repair has been the main treatment for IPA, particularly when the size of the pseudoaneurysm is larger than 4 cm or when anticoagulation or GP-IIb/IIIa inhibitors are extensively used during the procedure. However, if the site of the pseudoaneurysm, such as deep femoral artery, was more deeply located, thrombin injection might be simpler or more useful compared to surgical ligation. Here, we report the successful treatment of huge IPA by percutaneous thrombin injection in a case complicated with giant pseudoaneurysm of deep femoral artery after the endovascular intervention for peripheral arterial occlusive disease.

Coronary Artery Thrombosis Associated With Paclitaxel in Advanced Ovarian Cancer

A 63-year-old woman was diagnosed with ovarian cancer and peritoneal carcinomatosis. The day after paclitaxel was administered, an acute myocardial infarction occurred. Emergency coronary angiography revealed a filling defect in the left main coronary artery and total occlusion in the distal left anterior descending coronary artery, with no luminal irregularity or narrowing. Intravascular ultrasonography showed no significant plaque in the left main coronary artery. A thrombophilia work-up was negative, and the patient was treated with tirofiban, clopidogrel, and aspirin. The follow-up coronary angiogram showed that the occlusion of the distal obtuse marginal branch and distal left anterior descending artery had cleared. Paclitaxel has been associated with acute myocardial infarction. However, the pathogenesis of myocardial infarction associated with paclitaxel is not known. This case raises the possibility that paclitaxel can induce coronary artery thrombosis, resulting in myocardial infarction.